Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand

PharmacoEconomics

Volumn 32, Issue 7, 2014, Pages 707-724

  Webber Foster, Rachel ^a   Kvizhinadze, Giorgi ^a   Rivalland, Gareth ^b   Blakely, Tony ^a  

^a UNIVERSITY OF OTAGO WELLINGTON   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PIPERACILLIN PLUS TAZOBACTAM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXOID;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MULTIPLE CYCLE TREATMENT; NEW ZEALAND; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; UNCERTAINTY; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CANCER STAGING; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; ECONOMICS; MONTE CARLO METHOD; MORTALITY; PATHOLOGY; PROBABILITY; SURVIVAL;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; MONTE CARLO METHOD; NEOPLASM STAGING; NEW ZEALAND; PACLITAXEL; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS; TAXOIDS;

EID: 84903938098     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0154-x     Document Type: Article

References (61)

1. Ministry of Health. Cancer: new registrations and deaths 2010. Wellington: Ministry of Health; 2013.
2. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717. doi:10.1016/S0140-6736(05)66544-0.
3. Scottish Intercollegiate Guidelines Network. Management of breast cancer in women: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2005.
4. New Zealand Guidelines Group. Management of early breast cancer: evidence-based best practice guideline. Wellington; 2009.
5. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2007; (4):CD004421. doi:10.1002/14651858.CD004421.pub2.
6. Breast Cancer Disease Site Group. Adjuvant taxane therapy for women with early-stage, invasive breast cancer. Program in Evidence-based Care Evidence-Based Series No. 1-7 Version 2. Toronto (ON): Cancer Care Ontario; 2011.
7. National Breast and Ovarian Cancer Centre. Recommendations for use of taxane-containing chemotherapy regimens for the treatment of early (operable) breast cancer: clinical practice guideline. Sydney (NSW): Cancer Australia; 2008.
8. National Collaborating Centre for Cancer. Early and locally advanced breast cancer: diagnosis and treatment. London: National Institute for Health and Care Excellence (NICE); 2009.
9. PHARMAC. Proposal to widen access to docetaxel: consultation letter. Wellington: PHARMAC; 2011.
10. Wolowacz SE, Cameron DA, Tate HC, Bagust A. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol. 2008;26(6):925-33. doi:10.1200/JCO.2006.10.4190. (Pubitemid 351398086)
11. Au HJ, Golmohammadi K, Younis T, Verma S, Chia S, Fassbender K, et al. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects. Breast Cancer Res Treat. 2009;114(3):579-87. doi:10.1007/s10549-008- 0034-1.
12. Marino P, Siani C, Roche H, Protiere C, Fumoleau P, Spielmann M, et al. Cost-effectiveness of adjuvant docetaxel for nodepositive breast cancer patients: results of the PACS 01 economic study. Ann Oncol. 2010;21(7):1448-54. doi:10.1093/annonc/mdp561.
13. Younis T, Rayson D, Sellon M, Skedgel C. Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. Breast Cancer Res Treat. 2008;111(2):261-7. doi:10.1007/s10549-007-9770-x.
14. Younis T, Rayson D, Skedgel C. The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer. Curr Oncol. 2011;18(6):e288-96.
15. Martin-Jimenez M, Rodriguez-Lescure A, Ruiz-Borrego M, Segui-Palmer MA, Brosa-Riestra M. Cost-effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer. Clin Transl Oncol. 2009;11(1):41-7.
16. Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;11(40):1-144.
17. Limwattananon S, Limwattananon C, Maoleekulpairoj S, Soparatanapaisal N. Cost-effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancer. J Med Assoc Thail. 2006;89(5):690-8. (Pubitemid 43763899)
18. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663-71. doi:10.1056/NEJMoa0707056. (Pubitemid 351549913)
19. PHARMAC. New Zealand pharmaceutical schedule, vol. 18, no. 1. PHARMAC; Wellington; 2011.
20. PHARMAC. New Zealand pharmaceutical schedule: vol. 18, no. 2. PHARMAC; Wellington; 2011.
21. PHARMAC. New Zealand pharmaceutical schedule: section H for hospital pharmaceuticals. PHARMAC; Wellington; 2011.
22. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008;26(1):44-53. doi:10.1200/JCO.2007.11.3787.
23. Qin Y-Y, Li H, Guo X-J, Ye X-F, Wei X, Zhou Y-H, et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS One. 2011;6(11):e26946.
24. Bria E, Nistico C, Cuppone F, Carlini P, Ciccarese M, Milella M, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer. 2006;106(11):2337-44. (Pubitemid 43787656)
25. Giménez Poderós T, Gaminde Inda I, Iruin Sanz A, Napal Lecumberri V. Taxanos en el tratamiento adyuvante del cáncer de mama con ganglios positivos: metanálisis [Taxanes in the adjuvant therapy of breastcancer with positive nodes: a meta-analysis]. Farm Hosp. 2005;29:75-85. (Pubitemid 40872226)
26. Blakely T, Foster R, Wilson N, Bode3 Team. Burden of Disease Epidemiology, Equity and Cost-Effectiveness (BODE3) Study Protocol. Version 2.0. Wellington: Department of Public Health, University of Otago, Wellington; 2012.
27. Salmond C, Crampton P, Atkinson J. NZDep2006 index of deprivation. Wellington: Department of Public Health, University of Otago; 2007.
28. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258-66. doi:10.1002/cncr.21847. (Pubitemid 43673249)
29. Costilla R, Atkinson J, Blakely T. Incorporating ethnic and deprivation variation to cancer incidence estimates over 2006-2026 for the ABC-CBA model. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme-Technical Report No. 5. Wellington: Department of Public Health, University of Otago, Wellington; 2011.
30. Blakely T, Costilla R, Soeberg M. Cancer excess mortality rates over 2006-2026 for ABC-CBA. Burden of Disease Epidemiology, Equity and Cost-Effectiveness programme, Technical Report No. 10. Wellington: Department of Public Health, University of Otago, Wellington; 2012.
31. Kvizhinadze G, Blakely T. Projected New Zealand lifetables. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme (BODE3). Technical Report: No. 4. Wellington: Department of Public Health, University of Otago, Wellington; 2011.
32. Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24(36):5664-71. doi:10.1200/JCO.2006.07.3916. (Pubitemid 46631307)
33. Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst. 2008;100(11):805-14. doi:10.1093/jnci/djn151. (Pubitemid 351809668)
34. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2129-43. doi:10.1016/S0140-6736(12)61680-8.
35. Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011;29(29):3877-84. doi:10.1200/JCO.2010.28.5437.
36. Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet. 2009;373(9676):1681-92. doi:10.1016/S0140-6736(09)60740-6.
37. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-9. doi:10.1200/JCO.2003.09.081. (Pubitemid 46594092)
38. Loesch D, Greco FA, Senzer NN, Burris HA, Hainsworth JD, Jones S, et al. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. J Clin Oncol. 2010;28(18):2958-65. doi:10.1200/JCO.2009.24.1000.
39. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21(6):976-83. (Pubitemid 46594124)
40. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011;29(34):4491-7. doi:10.1200/JCO.2011.36.7045.
41. Madarnas Y, Dent SF, Husain SF, Robinson A, Alkhayyat S, Hopman WM, et al. Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres. Curr Oncol. 2011;18(3):119-25.
42. Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2011;125(3):767-74. doi:10.1007/s10549-010-1278-0.
43. Pharmaco (NZ) Limited. Data sheet: paclitaxel ebewe injection concentrate. Auckland; 2011.
44. Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol. 2008;6(6):455-67.
45. Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol. 2008;66(3):218-28. doi:10.1016/j.critrevonc.2008.01.008.
46. Foster R, Blakely T, Wilson N, O'Dea D. Protocol for direct costing of health sector interventions for economic modelling (including event pathways). Wellington: Department of Public Health, University of Otago; 2012.
47. van Baal PH, Feenstra TL, Polder JJ, Hoogenveen RT, Brouwer WB. Economic evaluation and the postponement of health care costs. Health Econ. 2011;20(4):432-45. doi:10.1002/hec.1599.
48. Statistics New Zealand. Gross domestic product. 2013. http://www.stats.govt.nz/browse-for-stats/economic-indicators/GDP/ GrossDomesticProduct-HOTPDec12qtr/Tables.aspx. Accessed 17 May 2013.
49. World Health Organization. CHOosing Interventions that are Cost Effective (WHO-CHOICE): cost-effectiveness thresholds. 2013. http://www.who.int/choice/ costs/CER-thresholds/en/. Accessed 17 May 2013.
50. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21(24):4524-31. doi:10.1200/JCO.2003.05. 002. (Pubitemid 46594022)
51. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332(14):901-6. doi:10.1056/NEJM199 504063321401.
52. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330(18):1253-9. doi:10.1056/NEJM199405053301801.
53. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8-32. doi:10.1016/j.ejca.2010.10.013.
54. Begg SJ, Vos T, Barker B, Stanley L, Lopez AD. Burden of disease and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors. Med J Aust. 2008;188(1):36-40.
55. Ministry of Health. The price of cancer: the public price of registered cancer in New Zealand. Wellington: University of Otago; 2011.
56. Ministry of Health, District Health Boards New Zealand. Purchase Unit Data Dictionary (PU DD) 2011/2012; 2011.
57. Ministry of Health. Guide to the National Travel Assistance (NTA) Policy 2005: August 2009. Wellington: Ministry of Health; 2009.
58. The National Pricing Programme Casemix Cost Weights Project Group. New Zealand casemix framework for publicly funded hospitals (including WIESNZ11 methodology and casemix purchase unit allocation) for the 20011/12 financial year: specification for implementation on NMDS. Wellington: District Health Boards New Zealand, Ministry of Health; 2011.
59. Ministry of Health. WIESNZ11 cost weights. Ministry of Health, Wellington. 2011. http://www.health.govt.nz/nz-health-statistics/data- references/weighted-inlier-equivalent-separations/wiesnz11-cost-weights. Accessed 7 March 2013.
60. Dooley MJ, Singh S, Michael M. Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer. 2004;12(9):653-6. doi:10.1007/s00520-004-0606-5. (Pubitemid 39280316)
61. Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One. 2010;5(1):e8933. doi:10.1371/journal.pone.0008933.